MedTrace Logo

Efficacy and Safety of HCP1102 Capsule

NCT02552667 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2015-09-17

No results posted yet for this study

Summary

Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.

Conditions

  • Asthma With Allergic Rhinitis

Interventions

DRUG

HCP1102+HGP0711Placebo

Coadministration of HCP1102 with HGP0711 Placebo for 4-week

DRUG

HCP1102Placebo+HGP0711

Coadministration of HCP1102 Placebo with HGP0711 for 4-week

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Choon-Sik Park, M.D., Ph.D. · Soon Chun Hyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552667 on ClinicalTrials.gov